Glucagon‐like peptide‐1 receptor agonists and upper endoscopy: a real‐world experience

Bibliographic Details
Main Authors:	Pichamol Jirapinyo, Noppachai Siranart, Christopher C. Thompson
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Obesity
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
by: Dario Giugliano, et al.
Published: (2025)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
by: Robert L. Dubin, et al.
Published: (2024)

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
by: Lien‐Chung Wei, et al.
Published: (2025)

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
by: Giovanni Antonio Silverii, et al.
Published: (2024)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
by: Claire H. Parker, et al.
Published: (2025)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
by: Lucas A. Mavromatis, et al.
Published: (2025)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
by: Jessica Van Laren, et al.
Published: (2026)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
by: David C. Klonoff, et al.
Published: (2024)

Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
by: Yu Mi Kang, et al.
Published: (2025)

Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies
by: Ronald M. Goldenberg, et al.
Published: (2025)

Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
by: Muhammad Aaqib Shamim, et al.
Published: (2024)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
by: Frederick Berro Rivera, et al.
Published: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
by: Darren Lau, et al.
Published: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
by: Filip K. Knop, et al.
Published: (2024)

Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
by: Sara Berg, et al.
Published: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
by: Karen L. Jones, et al.
Published: (2024)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
by: Andy Bowe, et al.
Published: (2025)

Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association
by: Anthony Nguyen, et al.
Published: (2024)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
by: Irl B. Hirsch, et al.
Published: (2024)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
by: Amanda R. Purcell, et al.
Published: (2025)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
by: Fu‐Shun Yen, et al.
Published: (2025)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
by: Yunwen Xu, et al.
Published: (2025)

Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
by: Mona Abdel‐Bary, et al.
Published: (2025)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
by: Iskandar Idris
Published: (2024)

The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
by: Victoria Wen Wei Ng, et al.
Published: (2024)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
by: Stephanie L. Samuels, et al.
Published: (2024)

Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study
by: Raffaele Napoli, et al.
Published: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
by: Jason M. Samuels, et al.
Published: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
by: Ruoyang Jiao, et al.
Published: (2024)

Effectiveness and care continuity in an app‐based, glucagon‐like peptide‐1 receptor agonist‐supported weight‐loss service for women with overweight and obesity in the UK : A real‐world retrospective cohort analysis
by: Louis Talay, et al.
Published: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
by: Julio Rosenstock, et al.
Published: (2025)

Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
by: Deep Dutta, et al.
Published: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
by: Tae Hyeon Kim, et al.
Published: (2024)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
by: Yi‐Chang Chou, et al.
Published: (2025)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
by: Conner E. Johnson, et al.
Published: (2024)

Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
by: Abraish Ali, et al.
Published: (2025)

Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue
by: Richard Sotorník, et al.
Published: (2025)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
by: Jincheng Shen, et al.
Published: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
by: Flora Lambert, et al.
Published: (2025)

FRONTIER : FReeStyle Libre system use in Ontario among people with diabetes in the IC / ES database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies
by: Alexandria Ratzki‐Leewing, et al.
Published: (2025)

Similar Items

Similar Items